Back to top

BioCryst (BCRX) Gets a Buy from Evercore ISI

Evercore ISI analyst maintained a Buy rating on BioCryst today and set a price target of $17.00. In a report released on August 6, H.C. Wainwright ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioCryst Pharmaceuticals, Inc. (BCRX)